Article

FDA Warnings on Unapproved Stem Cell Products: What They Say

A close reading of the FDA's own consumer warnings, the short list of products it has actually approved, and how much of it applies once you leave the United States.

October 31, 2026 · 10 min read · Last checked: October 31, 2026

The FDA's message to patients is narrow and firm. Outside a short list of approved products and properly authorized clinical trials, the agency treats stem cell and exosome products sold in the US as unapproved. It warns that they may be illegal and may carry real safety risks.

This article sets out what those warnings say, in plain terms. It does not argue for or against any treatment. Its purpose is to help you ask better questions before you spend money or travel.

The FDA pages behind this article

We relied on three FDA pages, each opened on October 31, 2026. Their dates matter, because one of them is older than a key approval.

Where the consumer pages and the approved-products list differ, the list is the more current record. We point out the one place this matters below.

What FDA has actually approved

Both consumer pages say the only FDA-approved stem cell products are blood-forming stem cells from umbilical cord blood. FDA adds that these are approved only for disorders affecting blood production, and "they are not approved for other uses."

The approved cord-blood products

The approved-products list names nine cord-blood products, all labeled "HPC, Cord Blood." HPC stands for hematopoietic progenitor cells, the cells that rebuild blood and immune systems.

These are public cord-blood bank products used in transplant medicine. They are not the umbilical, Wharton's jelly or "cord tissue" products that many clinics market for joints, nerves or aging.

The update the consumer pages miss

On December 18, 2024, FDA approved Ryoncil (remestemcel-L-rknd), made by Mesoblast, Inc. FDA called it the first mesenchymal stromal cell therapy it had approved. Its indication is narrow: steroid-refractory acute graft-versus-host disease in children 2 months of age and older.

Graft-versus-host disease is a complication of bone marrow or stem cell transplants. Ryoncil's approval does not extend to orthopedic, neurological, cosmetic or anti-aging uses. FDA's announcement also listed its own risks, including hypersensitivity, infusion reactions, transmission of infectious agents and ectopic tissue formation.

The approved list also includes other cell and gene therapies, such as CAR-T cancer treatments and a cultured cartilage-cell product. Each has its own labeled use. None of them makes a clinic's own cell preparation approved.

What FDA says about unapproved products

FDA says unapproved regenerative products continue to be marketed broadly for many diseases. It names the categories directly.

• Stem cells and stromal vascular fraction (cells taken from fat)
• Umbilical cord blood and cord blood stem cells
• Amniotic fluid and Wharton's jelly products
• Ortho-biologics
• Exosomes

FDA applies this whether the material comes from the patient or from a donor. For exosomes, the agency is blunt: no exosome product is currently FDA-approved.

Conditions FDA says are not approved uses

FDA lists conditions for which no regenerative therapy is approved. They include osteoarthritis, back and joint pain, ALS, Alzheimer's, Parkinson's, stroke, heart disease, COPD, COVID-19, autism, macular degeneration, blindness, chronic pain and fatigue.

The legal point: trials and INDs

FDA says these products must be studied under FDA oversight before they can be marketed. It has repeatedly told clinics and manufacturers that an Investigational New Drug application (IND) is needed to give them legally.

FDA also warns that paying for these products, or receiving them outside a clinical trial, may mean you are being deceived and offered a product illegally.

Two claims FDA specifically defuses

Clinics sometimes point to a ClinicalTrials.gov listing or to FDA registration as proof of legitimacy. FDA addresses both. It says a ClinicalTrials.gov listing, or a firm's registration with FDA, "does not mean the product is legally marketed."

We cover the registration claim in more depth in what "FDA registered" does and does not mean. The legal line between regulated drugs and lightly regulated tissue is explained in FDA 351 vs 361.

The risks FDA lists

FDA's patient page lists specific harms linked to unapproved regenerative products. We have grouped them below without changing their meaning.

What the published case reports add

A 2018 review in Stem Cells Translational Medicine by Bauer, Elsallab and Abou-El-Enein searched for reported harms after unproven stem cell interventions. It identified 35 cases of complications or death, from 19 scientific reports and 16 media reports.

The clinics involved were in 14 countries. Reported harms included tumors, infections, neurological and cardiovascular events, vision loss and autoimmune reactions. The authors said the true number is likely higher, because many cases are never reported.

That review cannot tell you how often harm happens. It shows the kinds of harm that have happened, in many places, after products sold outside approved pathways.

How this applies to treatment abroad

FDA is a US regulator. Its approvals, warnings and enforcement apply to products made, sold or given in the United States. FDA does not license clinics in Colombia or anywhere else outside the US.

That cuts both ways. A treatment being legal to offer in Colombia does not make it FDA-approved. And an FDA warning letter to a US company does not, by itself, govern a clinic in Medellín or Bogotá.

Which regulator to ask about

In Colombia, the national health products regulator is INVIMA, which works under the Ministry of Health and Social Protection. In a 2017 presentation, INVIMA described its regulatory route for advanced therapies as still being developed. Ask any clinic what has changed since, and ask for document numbers.

Our explainer on how INVIMA regulates stem cell therapy covers the Colombian side in more detail. The ISSCR's patient questions frame it simply: ask whether a national or regional regulator has approved the treatment for your condition.

Why the FDA warnings still matter to you

• The risks are biological, not legal. Contamination, infection and immune reactions do not depend on which country you are in.
• Your follow-up care is likely at home. If a complication shows up after you return, your US doctors will need full records of what you received.
• The evidence gap is the same. FDA's list of unapproved uses reflects missing proof of safety and benefit, not just paperwork.
• Insurance may not follow you. The ISSCR advises checking what your insurance covers, in what circumstances and in what countries, before you travel.

Questions to ask a clinic before you pay

These questions come from the risk areas FDA names and from the ISSCR's patient guidance. Ask for written answers. A spoken reassurance is not documentation.

1. What exactly is the product? Ask for the cell source, how cells are isolated and grown, and how they are given.
2. What is its regulatory status, and where? Ask which national regulator authorized it, for which condition, with the authorization number.
3. Is this part of a registered trial? If yes, ask for the registry ID and the ethics committee approval. If you are asked to pay to join, ask why.
4. How was it tested? Ask for sterility, endotoxin and mycoplasma results and donor screening for infections such as hepatitis and HIV.
5. What are the immediate and long-term risks? Ask how the clinic handles a severe allergic reaction, and who you call in an emergency.
6. Who is the responsible doctor? Ask for their name, specialty and training.
7. Who pays if something goes wrong? Ask about emergency care, long-term complications and whether you would need to sue to be compensated.
8. What will I receive in writing afterward? Ask for a treatment record your home doctor can read.

For the lab side, see what a certificate of analysis should show.

Reporting a problem

FDA asks patients to report serious side effects from regenerative medicine products through MedWatch, its adverse event reporting program. Health professionals can report there too.

For questions about a product's approval status, or if you are offered one outside an FDA-overseen trial, FDA lists a phone line (800-835-4709) and an email address (ocod@fda.hhs.gov).

If you were treated in Colombia, the clinic and Colombian authorities are the bodies with direct jurisdiction. Keep every record, invoice and product label in case you need them.

Disclosure: If you ask us for provider options, your inquiry may be shared with up to three providers, and participating providers may compensate our network. That does not change what FDA says or what you should ask for.